FOR BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS
Superiority vs Humira at week 24: Simultaneous achievement of ACR50 and PASI 100 at week 24, with consistency at week 526
SELECT IMPORTANT SAFETY INFORMATION
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.